Development

Feliza Mirasol is the science editor for 

Articles

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion 

Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.

Compounding Overview: Primary Considerations in the Workplace

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, talks about the differences in designing E&L testing for combination products vs. conventional pharmaceuticals.

Distinguishing E&L Testing for Combination Products (AAPS PharmSci 360)

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, recommends some key issues that pharma manufacturers should consider when formulating products that require a medical device.

Key E&L Issues to Consider During Formulation (AAPS PharmSci 360)

The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth. 

Phase III Study for Novel Ganaplacide/Lumefantrine-SDF Combination in Adults, Children with Malaria Announced

Markus Hörburger is product and service manager Secondary Packaging & Device Assembly at Vetter.

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

Converting Injectable Therapies to Combination Drug-Device Products

The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.

Owen Mumford and Stevanato Group Collaborate on Auto-Injector

AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.

AstraZeneca’s AZD7442 Clinical Trial Meets Primary Endpoint

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.

Formulating Tablets Layer by Layer

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of AstraZeneca’s Qtrilmet (metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets for treating type-2 diabetes.

Formulation and Drug Delivery, Combination Drugs